一种用于抑制不同蛋白质聚合途径的类策略.
Tommaso Garfagnini1, Luca Ferrari2,3,4, Margreet B Koopman2,3
1Institute of Chemistry, The Hebrew University of Jerusalem, Edmond J. Safra Campus at Givat Ram, 9190401, Jerusalem, Israel.
Chemistry (Weinheim an der Bergstrasse, Germany)
|July 7, 2024
概括
研究人员开发了新型,可以抑制蛋白质聚合,这是许多疾病的关键因素. 这些多重向化合物显示出开发针对各种蛋白质聚合障碍的新疗法的前景.
科学领域:
- 生物化学和分子生物学
- 药物发现和开发 药物发现和开发
- 神经退行性疾病 神经退行性疾病
背景情况:
- 蛋白质聚合与许多人类疾病有关,包括阿尔茨海默氏症和亨廷顿病.
- 开发有效的蛋白质聚合抑制剂的现有策略在临床翻译中面临着重大挑战.
- 蛋白质聚合物表现出多样化的结构和形状,使通用抑制剂的发展复杂化.
研究的目的:
- 开发一种针对蛋白质聚合早期阶段的新型抑制剂.
- 研究这些的潜力,以抑制无形和纤维状蛋白质聚合物.
- 确定控制这些交叉机制聚合抑制剂疗效的关键分子决定因素.
主要方法:
- 利用基阵列来选无形聚合抑制剂,使用Axin瘤抑制剂的聚合易感突变物.
- 基于分子决定因素的优化序列,如残留物组成,疏水性和分布.
- 评估了优化对陶纤维化 (阿尔茨海默氏症) 和亨廷丁exon1聚合 (亨廷顿病) 的抑制活性.
主要成果:
- 鉴定出一种针对Axin的早期无形聚合有效的类家族.
- 确定的有效性取决于特定的分子特征 (残留成分,疏水性,分布),而不是序列.
- 证明这些可以抑制纤维化和减缓亨廷丁外因子1聚合,尽管有序列和结构上的差异.
结论:
- 开发了针对多种蛋白质聚合途径有效的跨机制,多向的抑制剂.
- 这些可以向动态聚合前体,提供一种新的治疗策略.
- 鉴定到的特征为开发针对一系列蛋白质聚合疾病的候选药物提供了基础.
更多相关视频
14:28Peptide-based Identification of Functional Motifs and their Binding Partners
Published on: June 30, 2013
12.4K
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
11.3K
相关概念视频
Protein Folding
7.9K
Proteins are chains of amino acids linked together by peptide bonds. Upon synthesis, a protein folds into a three-dimensional conformation, critical to its biological function. Interactions between its constituent amino acids guide protein folding, and hence the protein structure is primarily dependent on its amino acid sequence.
Protein Structure Is Critical to Its Biological Function
Proteins perform a wide range of biological functions such as catalyzing chemical reactions, providing...
Protein Structure Is Critical to Its Biological Function
Proteins perform a wide range of biological functions such as catalyzing chemical reactions, providing...
7.9K
The Proteasome
827
Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
827
Amyloid Fibrils
9.5K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.5K
Protein-protein Interfaces
12.5K
Many proteins form complexes to carry out their functions, making protein-protein interactions (PPIs) essential for an organism's survival. Most PPIs are stabilized by numerous weak noncovalent chemical forces. The physical shape of the interfaces determines the way two proteins interact. Many globular proteins have closely-matching shapes on their surfaces, which form a large number of weak bonds. Additionally, many PPIs occur between two helices or between a surface cleft and a...
12.5K
